Free Trial
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Takeda Pharmaceutical logo
$14.46 +0.10 (+0.70%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$14.45 -0.01 (-0.07%)
As of 08/8/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Takeda Pharmaceutical Stock (NYSE:TAK)

Key Stats

Today's Range
$14.38
$14.49
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.53
Volume
3.05 million shs
Average Volume
5.69 million shs
Market Capitalization
$46.01 billion
P/E Ratio
48.20
Dividend Yield
3.80%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Takeda Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

TAK MarketRank™: 

Takeda Pharmaceutical scored higher than 51% of companies evaluated by MarketBeat, and ranked 541st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Takeda Pharmaceutical are expected to grow by 0.61% in the coming year, from $1.64 to $1.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Takeda Pharmaceutical is 48.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Takeda Pharmaceutical is 48.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.75.

  • Price to Book Value per Share Ratio

    Takeda Pharmaceutical has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.14% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently decreased by 11.00%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.84%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Takeda Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Takeda Pharmaceutical is 183.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 33.33% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Takeda Pharmaceutical's dividend.
  • Percentage of Shares Shorted

    0.14% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently decreased by 11.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Takeda Pharmaceutical has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for TAK on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

  • Read more about Takeda Pharmaceutical's insider trading history.
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Takeda Pharmaceutical 1Q Net Y124.24B Vs Net Y95.25B
See More Headlines

TAK Stock Analysis - Frequently Asked Questions

Takeda Pharmaceutical's stock was trading at $13.24 at the beginning of 2025. Since then, TAK stock has increased by 9.2% and is now trading at $14.46.

Takeda Pharmaceutical Co. (NYSE:TAK) issued its quarterly earnings data on Wednesday, July, 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a trailing twelve-month return on equity of 10.50%.
Read the conference call transcript
.

Takeda Pharmaceutical subsidiaries include these companies: PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and more.

Top institutional shareholders of Takeda Pharmaceutical include Envestnet Asset Management Inc. (0.03%), QRG Capital Management Inc. (0.01%), Creative Planning (0.01%) and Bleakley Financial Group LLC (0.01%).
View institutional ownership trends
.

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

Last Earnings
7/30/2025
Today
8/08/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:TAK
CIK
1395064
Employees
47,455
Year Founded
1781

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
48.22
Forward P/E Ratio
8.82
P/E Growth
N/A
Net Income
$712.33 million
Net Margins
3.20%
Pretax Margin
3.82%
Return on Equity
10.50%
Return on Assets
5.10%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
1.16
Quick Ratio
0.59

Sales & Book Value

Annual Sales
$30.09 billion
Price / Sales
1.53
Cash Flow
$3.22 per share
Price / Cash Flow
4.49
Book Value
$14.89 per share
Price / Book
0.97

Miscellaneous

Outstanding Shares
3,181,930,000
Free Float
3,180,652,000
Market Cap
$46.03 billion
Optionable
Optionable
Beta
0.22

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:TAK) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners